Canada markets open in 7 hours 39 minutes
  • S&P/TSX

    20,154.54
    -335.82 (-1.64%)
     
  • S&P 500

    4,357.73
    -75.26 (-1.70%)
     
  • DOW

    33,970.47
    -614.41 (-1.78%)
     
  • CAD/USD

    0.7833
    +0.0027 (+0.34%)
     
  • CRUDE OIL

    71.10
    +0.81 (+1.15%)
     
  • BTC-CAD

    54,229.38
    -4,490.27 (-7.65%)
     
  • CMC Crypto 200

    1,060.21
    -74.17 (-6.54%)
     
  • GOLD FUTURES

    1,763.10
    -0.70 (-0.04%)
     
  • RUSSELL 2000

    2,182.20
    -54.67 (-2.44%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,070.25
    +60.75 (+0.40%)
     
  • VOLATILITY

    25.71
    +4.90 (+23.55%)
     
  • FTSE

    6,903.91
    -59.73 (-0.86%)
     
  • NIKKEI 225

    29,974.03
    -526.02 (-1.72%)
     
  • CAD/EUR

    0.6672
    +0.0024 (+0.36%)
     

Replimune to Present at the William Blair Biotech Focus Conference 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting